View larger
NCK Adaptor Protein 1 Human Recombinant ( NCK1 Human )
DescriptionNCK1 Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 397 amino acids (1-377 a.a.) and having a molecular mass of 45 kDa. The NCK1 is fused to 20 amino acid His-Tag at N-terminus and purified
Data sheet
| Formulation | NCK1 Human solution containing 20mM Tris-HCl pH-8, 1mM DTT, 1mM EDTA, 50mM NaCl & 20% glycerol. |
| Purity | Greater than 90.0% as determined by SDS-PAGE. |
| Description | NCK1 Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 397 amino acids (1-377 a.a.) and having a molecular mass of 45 kDa. The NCK1 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques. |
| Protein Background | NCK1 is an adapter protein which binds with tyrosine-phosphorylated growth factor receptors or their cellular substrates. NCK1 maintains low levels of EIF2S1 phosphorylation by promoting its dephosphorylation by PP1. NCK1 is involved in the DNA damage response, for efficient activation of downstream effectors, such as that of CHEK2. NCK1 is one of the signaling and transforming proteins containing Src homology 2 and 3 (SH2 and SH3) domains. NCK1 is located in the cytoplasm and is an adaptor protein that participates in transducing signals from receptor tyrosine kinases to downstream signal recipients such as RAS. |
| Expression host | Escherichia Coli. |
| Synonyms | NCK, NCKalpha, NCK1, NCK adaptor protein 1, Cytoplasmic protein NCK1, SH2/SH3 adaptor protein NCK-alpha, MGC12668. |
| Reagent Appearance | Sterile filtered colorless solution. |
| Stability | Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles. |
| Amino acid sequence | MGSSHHHHHH SSGLVPRGSH MAEEVVVVAK FDYVAQQEQE LDIKKNERLW LLDDSKSWWR VRNSMNKTGF VPSNYVERKN SARKASIVKN LKDTLGIGKV KRKPSVPDSA SPADDSFVDP GERLYDLNMP AYVKFNYMAE REDELSLIKG TKVIVMEKCS DGWWRGSYNG QVGWFPSNYV TEEGDSPLGD HVGSLSEKLA AVVNNLNTGQ VLHVVQALYP FSSSNDEELN FEKGDVMDVIEKPENDPEWW KCRKINGMVG LVPKNYVTVM QNNPLTSGLE PSPPQCDYIR PSLTGKFAGN PWYYGKVTRH QAEMALNERG HEGDFLIRDS ESSPNDFSVS LKAQGKNKHF KVQLKETVYC IGQRKFSTME ELVEHYKKAP IFTSEQGEKL YLVKHLS. |
| Immunological Activity | Thimerosal and beta propiolactone treatmentThis product has been treated in a manner consistent with methods of inactivation. Generally accepted good laboratory practices appropriate to microbiological/viral safe handling practices and techniques are required at work. |
| Reference | Tested with anti-influenza A monoclonal antibodies in ELISA.Serological studies of influenza A virus, immunogen for antibody production. |